Indian J Pharm Close
 

Figure 2: Recommendation for non-small cell lung cancer patients with central nervous system metastases. BM, brain metastasis; CNS, central nervous system; EGFR, epidermal growth receptor; Fr, fraction; Gy, Gray; NSCLC, non-small cell lung cancer, SRS, stereotactic radiosurgery, TKI, tyrosine kinase inhibitors; WBRT, whole-brain radiotherapy. *Data in second line setting suggest that immunotherapy is less effective, irrespective of PD-L1 expression, in tumors with an actionable mutation

Figure 2: Recommendation for non-small cell lung cancer patients with central nervous system metastases. BM, brain metastasis; CNS, central nervous system; EGFR, epidermal growth receptor; Fr, fraction; Gy, Gray; NSCLC, non-small cell lung cancer, SRS, stereotactic radiosurgery, TKI, tyrosine kinase inhibitors; WBRT, whole-brain radiotherapy. *Data in second line setting suggest that immunotherapy is less effective, irrespective of PD-L1 expression, in tumors with an actionable mutation